{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/rheumatoid-arthritis/management/covid-19/","result":{"pageContext":{"chapter":{"id":"c490cb4d-f228-5c81-b9f2-0ac419b6d60a","slug":"covid-19","fullItemName":"Scenario: COVID-19","depth":2,"htmlHeader":"<!-- begin field 86acd6c9-5060-47cc-8a3f-ab9500ae4944 --><h2>Scenario: COVID-19 Management</h2><!-- end field 86acd6c9-5060-47cc-8a3f-ab9500ae4944 -->","summary":"Covers management when considering the possibility of COVID-19.","htmlStringContent":"<!-- begin item ec68dfd4-2803-4704-abd5-ab9500ae4903 --><!-- begin field c613915d-5813-41be-b459-acbc015bf8b0 --><p>From birth onwards.</p><!-- end field c613915d-5813-41be-b459-acbc015bf8b0 --><!-- end item ec68dfd4-2803-4704-abd5-ab9500ae4903 -->","topic":{"id":"80425c66-11ed-5a54-aecf-455f339cb0cd","topicId":"d9596563-d663-48ca-8d6a-4ddeb263b46e","topicName":"Rheumatoid arthritis","slug":"rheumatoid-arthritis","lastRevised":"Last revised in April 2020","chapters":[{"id":"e5b4cb7c-c830-59e0-a369-a8151bd28e7c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"28d53d37-f5b2-5ab0-bd6f-6c6858fc63e4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"8eb76d85-83a8-5bb1-be89-15a9e86def8d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"7eba8b39-2fb0-52b0-8988-5d108c1720fa","slug":"changes","fullItemName":"Changes"},{"id":"add57644-4b68-5377-b8ce-b0cc395570f0","slug":"update","fullItemName":"Update"}]},{"id":"62d68b4b-4522-5afb-88fe-48b87fc31a2d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f9fe7005-bf48-5a4e-bc7c-08550e792a18","slug":"goals","fullItemName":"Goals"},{"id":"cc0b2b43-25e2-5936-ad94-217419fd0126","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6a0fead6-ca32-5399-9b1b-22b31fc0c765","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f76001a5-99f4-5086-bc05-c1cd7535aab0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"fb29501f-d465-5652-b659-ffb4e5c8e928","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3181265d-dee9-5587-974d-b4bae95c10ee","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"167941e5-411a-5afd-94af-8e7725b24b1a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"bb48f4e9-23c4-5828-bccb-666f4dbc512d","slug":"definition","fullItemName":"Definition"},{"id":"06cc7595-3f6c-59d6-929b-964159afde4d","slug":"prevalence-incidence","fullItemName":"Prevalence and incidence"},{"id":"8fb1fc93-039a-5d6b-a86d-aeb61578f11d","slug":"complications","fullItemName":"Complications"}]},{"id":"e352008d-7a0c-55ba-b778-c6218ef4ef69","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b9d257ab-0ebb-52bf-908a-8ebebe6c550c","slug":"when-to-suspect-ra","fullItemName":"When to suspect RA"},{"id":"25d80dc3-ea8a-5560-8a0b-3a64b87c5690","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"5de822df-3081-5ed6-a21b-e3e2925436bd","slug":"investigations-for-suspected-ra","fullItemName":"Investigations for suspected RA"}]},{"id":"6f1e7941-f462-5d64-8822-8328310b81b9","fullItemName":"Management","slug":"management","subChapters":[{"id":"2ed609a5-1052-56f5-b263-63d4e5325949","slug":"suspected-ra","fullItemName":"Scenario: Suspected RA"},{"id":"0ba5ec6e-3f0f-5157-8e24-55ef24b2cfe9","slug":"confirmed-ra","fullItemName":"Scenario: Confirmed RA"},{"id":"c490cb4d-f228-5c81-b9f2-0ac419b6d60a","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"13cb1ed1-b962-5e8a-88c8-8b7185af06df","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e875cc8d-258b-5535-9d34-40f03cb150c7","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9b45cf27-1cfb-591d-a936-5e49910f88ac","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"93bd3cb0-31a7-5acf-bc5f-8858b54e466b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a24a6436-a685-5277-8c22-524ebe895154","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4258a438-16bd-591d-bd95-5d6a682e1696","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"58298e48-e237-5259-b79b-da11e96f0a4e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6c1abdea-39c1-5537-8e4f-6e6ff3a71736","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6f1e7941-f462-5d64-8822-8328310b81b9","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"d978aa07-2a37-514e-bb1f-fde2ad57f430","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field c0f530d5-eb92-4b51-b722-ab9500ae4946 --><h3>How should my management vary when considering the possibility of COVID-19?</h3><!-- end field c0f530d5-eb92-4b51-b722-ab9500ae4946 -->","summary":null,"htmlStringContent":"<!-- begin item f28e9884-c2f7-45c2-a6db-ab9500ae4946 --><!-- begin field deb5d5b4-4129-4ea0-ad2e-ab9500ae4946 --><h4>People with suspected or known COVID-19 infection</h4><ul><li>Be aware that people having immunosuppressant treatments may have atypical presentations of COVID‑19. For example, people taking prednisolone may not develop a fever, and those taking interleukin‑6 inhibitors may not develop a rise in C‑reactive protein.</li><li>In people with rheumatoid disease suspected to have, or with known, COVID‑19, the recommendations are that they should:<ul><li>Continue hydroxychloroquine and sulfasalazine.</li><li>Not suddenly stop prednisolone.</li><li>Only have corticosteroid injections if the person has significant disease activity and there are no alternatives, and discuss with their specialist before doing so.</li><li>Temporarily stop other disease-modifying antirheumatic drugs, JAK inhibitors and biological therapies, and tell them to contact their rheumatology department for advice on when to restart treatment.</li></ul></li></ul><h4>Management of other therapies for asymptomatic people</h4><ul><li>Nonsteroidal anti-inflammatory drugs<ul><li>Advise people taking a nonsteroidal anti-inflammatory drug for a long-term condition such as rheumatoid arthritis that it does not need to be stopped.</li></ul></li><li>Corticosteroids<ul><li>Advise people taking prednisolone that it should not be stopped suddenly. They may wish to discuss lowering their dose in consultation with their specialist.</li></ul></li><li>Biological treatments<ul><li>These people may be assessed and moved from intravenous to subcutaneous treatment or from subcutaneous to oral treatment. They may also have the duration periods between treatments increased.</li></ul></li><li>Immunoglobulins<ul><li>People on this therapy may have the duration periods between treatments increased.</li></ul></li><li>Bisphosphonates and denosumab<ul><li>Do not postpone treatment with denosumab.</li></ul></li><li>Zoledronate<ul><li>Note that treatment with zoledronate can be postponed for up to 6 months.</li></ul></li></ul><h4>Drug monitoring</h4><ul><li>People starting a new disease-modifying antirheumatic drug should follow recommended blood monitoring guidelines. When this is not possible, they should contact the relevant specialist for advice.</li><li>In consultation with their specialist, each person may be able to safely increase the time interval between blood tests for drug monitoring, particularly if 3‑monthly blood tests have been stable for more than 2 years.</li></ul><!-- end field deb5d5b4-4129-4ea0-ad2e-ab9500ae4946 --><!-- end item f28e9884-c2f7-45c2-a6db-ab9500ae4946 -->","subChapters":[{"id":"231abbf6-568a-5fb3-b1e8-65e5efe6be77","slug":"basis-for-recommendation-ff9","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 263b852f-3ccd-4851-9af3-ab9500ae4948 --><h4>Basis for recommendation</h4><!-- end field 263b852f-3ccd-4851-9af3-ab9500ae4948 -->","summary":null,"htmlStringContent":"<!-- begin item ff95a944-e2c8-4c23-b9a2-ab9500ae4948 --><!-- begin field db85e9f2-93dd-4e08-a50c-ab9500ae4948 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) <em>COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">NICE, 2020</a>].</p><!-- end field db85e9f2-93dd-4e08-a50c-ab9500ae4948 --><!-- end item ff95a944-e2c8-4c23-b9a2-ab9500ae4948 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}